Skip to main content
SpringerLink
Log in

Benign Cutaneous Eruptions After Transplantation

  • Chapter
  • First Online:
Skin Diseases in the Immunosuppressed

  • 510 Accesses

Abstract

This chapter explores cutaneous diseases that are present in immunosuppressed solid organ transplant recipients. A chronologic approach begins with the cutaneous manifestations of end-stage kidney and liver disease. Subsequently, the cutaneous complications of induction therapy followed by posttransplant immunosuppression are organized by immunosuppressive agent and time to onset of each cutaneous eruption.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Udayakumar P, Balasubramanian S, Ramalingam KS, Lakshmi C, Srinivas CR, Mathew AC. Cutaneous manifestations in patients with chronic renal failure on hemodialysis. Indian J Dermatol Venereol Leprol. 2006;72(2):119–25.

    Article  CAS  PubMed  Google Scholar 

  2. Patel TS, Freedman BI, Yosipovitch G. An update on pruritus associated with CKD. Am J Kidney Dis. 2007;50(1):11–20.

    Article  PubMed  Google Scholar 

  3. Pisoni RL, Wikstrom B, Elder SJ, Akizawa T, Asano Y, Keen ML, Saran R, Mendelssohn DC, Young EW, Port FK. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006;21(12):3495–505.

    Article  PubMed  Google Scholar 

  4. Kuypers DR. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol. 2009;5(3):157–70.

    PubMed  Google Scholar 

  5. Kimmel M, Alscher DM, Dunst R, Braun N, Machleidt C, Kiefer T, Stulten C, van der Kuip H, Pauli-Magnus C, Raub U, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant. 2006;21(3):749–55.

    Article  CAS  PubMed  Google Scholar 

  6. Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M, laina A. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet. 1996;348(9041):1552–4.

    Article  CAS  PubMed  Google Scholar 

  7. Robinson-Bostom L, DiGiovanna JJ. Cutaneous manifestations of end-stage renal disease. J Am Acad Dermatol. 2000;43(6):975–86;quiz 87–90.

    Article  CAS  PubMed  Google Scholar 

  8. Morton CA, Henderson IS, Jones MC, Lowe JG. Acquired perforating dermatosis in a British dialysis population. Br J Dermatol. 1996;135(5):671–7.

    Article  CAS  PubMed  Google Scholar 

  9. Hood AF, Hardegen GL, Zarate AR, Nigra TP, Gelfand MC. Kyrle’s disease in patients with chronic renal failure. Arch Dermatol. 1982;118(2):85–8.

    Article  CAS  PubMed  Google Scholar 

  10. Patterson JW. The perforating disorders. J Am Acad Dermatol. 1984;10(4):561–81.

    Article  CAS  PubMed  Google Scholar 

  11. Oh DH, Eulau D, Tokugawa DA, McGuire JS, Kohler S. Five cases of calciphylaxis and a review of the literature. J Am Acad Dermatol. 1999;40(6 Pt 1):979–87.

    Article  CAS  PubMed  Google Scholar 

  12. Hafner J, Keusch G, Wahl C, Burg G. Calciphylaxis: a syndrome of skin necrosis and acral gangrene in chronic renal failure. VASA Zeitschrift fur Gefasskrankheiten. 1998;27(3):137–43.

    CAS  PubMed  Google Scholar 

  13. Strazzula L, Nigwekar SU, Steele D, Tsiaras W, Sise M, Bis S, Smith GP, Kroshinsky D. Intralesional sodium thiosulfate for the treatment of calciphylaxis. JAMA Dermatol. 2013;149(8):946–9.

    Article  PubMed  Google Scholar 

  14. Basile C, Montanaro A, Masi M, Pati G, De Maio P, Gismondi A. Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol. 2002;15(6):676–80.

    PubMed  Google Scholar 

  15. Savoia F, Gaddoni G, Patrizi A, Misciali C, Odorici G, Tampieri G, Tampieri E, Cantelli S, Aldi M. Calciphylaxis in dialysis patients, a severe disease poorly responding to therapies: report of 4 cases. G Ital Dermatol Venereol. 2013;148(5):531–6.

    CAS  PubMed  Google Scholar 

  16. Alagheband M, Engineer L. Lithium and halogenoderma. Arch Dermatol. 2000;136(1):126–7.

    Article  CAS  PubMed  Google Scholar 

  17. Vaillant L, Pengloan J, Blanchier D, De Muret A, Lorette G. Iododerma and acute respiratory distress with leucocytoclastic vasculitis following the intravenous injection of contrast medium. Clin Exp Dermatol. 1990;15(3):232–3.

    Article  CAS  PubMed  Google Scholar 

  18. Bolognia J, Jorizzo JL, Schaffer JV. Philadelphia; London: Elsevier Saunders; 2012:1 online resource (2 v. in 1).

    Google Scholar 

  19. Cordoliani F, Rybojad M, Morel P, Puissant A. Halogenoderma and monoclonal gammopathy. J Am Acad Dermatol. 1991;25(6 Pt 1):1099.

    Article  CAS  PubMed  Google Scholar 

  20. Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis. 2012;16(2):331–46.

    Article  PubMed  Google Scholar 

  21. Terry R. White nails in hepatic cirrhosis. Lancet. 1954;266(6815):757–9.

    Article  CAS  PubMed  Google Scholar 

  22. Tanriover B, Chuang P, Fishbach B, Helderman JH, Kizilisik T, Nylander W, Shaffer D, Langone AJ. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation. 2005;80(2):279–81.

    Article  CAS  PubMed  Google Scholar 

  23. Lundquist AL, Chari RS, Wood JH, Miller GG, Schaefer HM, Raiford DS, Wright KJ, Gorden DL. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl. 2007;13(5):647–50.

    Article  PubMed  Google Scholar 

  24. Steiner RW, Awdishu L. Steroids in kidney transplant patients. Semin Immunopathol. 2011;33(2):157–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Shibasaki F, Hallin U, Uchino H. Calcineurin as a multifunctional regulator. J Biochem. 2002;131(1):1–15.

    Article  CAS  PubMed  Google Scholar 

  26. Yu HJ, Lee SK, Son SJ, Kim YS, Yang HY, Kim JH. Steroid acne vs. Pityrosporum folliculitis: the incidence of Pityrosporum ovale and the effect of antifungal drugs in steroid acne. Int J Dermatol. 1998;37(10):772–7.

    Article  CAS  PubMed  Google Scholar 

  27. Mills OH Jr, Leyden JJ, Kligman AM. Tretinoin treatment of steroid acne. Arch Dermatol. 1973;108(3):381–4.

    Article  PubMed  Google Scholar 

  28. Mahe E, Morelon E, Lechaton S, Drappier JC, de Prost Y, Kreis H, Bodemer C. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol. 2006;55(1):139–42.

    Article  PubMed  Google Scholar 

  29. Liu LS, McNiff JM, Colegio OR. Palmoplantar peeling secondary to sirolimus therapy. Am J Transplant. 2014;14(1):221–5.

    Article  CAS  PubMed  Google Scholar 

  30. Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transpl. 2010;24(2):149–56.

    Article  CAS  Google Scholar 

  31. Scully C. Clinical practice. Aphthous ulceration. N Engl J Med. 2006;355(2):165–72.

    Article  CAS  PubMed  Google Scholar 

  32. Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010;116(1):210–5.

    CAS  PubMed  Google Scholar 

  33. MacDonald AS, Group RGS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001;71(2):271–80.

    Article  CAS  PubMed  Google Scholar 

  34. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet. 2000;356(9225):194–202.

    Article  CAS  PubMed  Google Scholar 

  35. van Gelder T, ter Meulen CG, Hene R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation. 2003;75(6):788–91.

    Article  PubMed  Google Scholar 

  36. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87(2):233–42.

    Article  CAS  PubMed  Google Scholar 

  37. Olczak-Kowalczyk D, Pawlowska J, Cukrowska B, Kluge P, Witkowska-Vogtt E, Dzierzanowska-Fangrat K, Wrzesniewska D, Smirska E, Grenda R. Local presence of cytomegalovirus and Candida species vs oral lesions in liver and kidney transplant recipients. Ann Transplant. 2008;13(4):28–33.

    PubMed  Google Scholar 

  38. Sharma S, Dasroy SK. Images in clinical medicine. Gingival hyperplasia induced by phenytoin. N Engl J Med. 2000;342(5):325.

    Article  CAS  PubMed  Google Scholar 

  39. Yu DS, Lee YB. Images in clinical medicine. Medication-induced gingival hypertrophy. N Engl J Med. 2009;360(2):e2.

    Article  CAS  PubMed  Google Scholar 

  40. Nakib N, Ashrafi SS. Drug-induced gingival overgrowth. Dis Mon. 2011;57(4):225–30.

    Article  PubMed  Google Scholar 

  41. Hallmon WW, Rossmann JA. The role of drugs in the pathogenesis of gingival overgrowth. A collective review of current concepts. Periodontology. 1999;21:176–96.

    Article  CAS  Google Scholar 

  42. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol. 1996;23(3 Pt 1):165–75.

    Article  CAS  PubMed  Google Scholar 

  43. Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation. 2002;74(6):804–8.

    Article  CAS  PubMed  Google Scholar 

  44. Desai N, Heenan S, Mortimer PS. Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism. Br J Dermatol. 2009;160(6):1322–6.

    Article  CAS  PubMed  Google Scholar 

  45. Huber S, Bruns CJ, Schmid G, Hermann PC, Conrad C, Niess H, Huss R, Graeb C, Jauch KW, Heeschen C, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. 2007;71(8):771–7.

    Article  CAS  PubMed  Google Scholar 

  46. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, Ishikura H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci. 2007;98(5):726–33.

    Article  CAS  PubMed  Google Scholar 

  47. Wysocki GP, Daley TD. Hypertrichosis in patients receiving cyclosporine therapy. Clin Exp Dermatol. 1987;12(3):191–6.

    Article  CAS  PubMed  Google Scholar 

  48. Taylor M, Ashcroft AT, Messenger AG. Cyclosporin A prolongs human hair growth in vitro. J Invest Dermatol. 1993;100(3):237–9.

    Article  CAS  PubMed  Google Scholar 

  49. Gafter-Gvili A, Sredni B, Gal R, Gafter U, Kalechman Y. Cyclosporin A-induced hair growth in mice is associated with inhibition of calcineurin-dependent activation of NFAT in follicular keratinocytes. Am J Physiol Cell Physiol. 2003;284(6):C1593–603.

    Article  CAS  PubMed  Google Scholar 

  50. Gafter-Gvili A, Kalechman Y, Sredni B, Gal R, Gafter U. Cyclosporin A-induced hair growth in mice is associated with inhibition of hair follicle regression. Arch Dermatol Res. 2004;296(6):265–9.

    Article  CAS  PubMed  Google Scholar 

  51. Boudou P, Fiet J, Vexiau P, Villette JM, Hardy N, Dreux C. Greater conversion of testosterone to 5 alpha-dihydrotestosterone, reflecting increased peripheral 5 alpha-reductase activity in nude mice treated with high doses of cyclosporine A. J Steroid Biochem. 1990;36(6):597–601.

    Article  CAS  PubMed  Google Scholar 

  52. Thorp M, DeMattos A, Bennett W, Barry J, Norman D. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation. 2000;69(6):1218–20.

    Article  CAS  PubMed  Google Scholar 

  53. Kim HC, Hwang EA, Han SY, Park SB, Kim HT, Cho WH. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. Transplant Proc. 2004;36(7):2082–3.

    Article  CAS  PubMed  Google Scholar 

  54. Tricot L, Lebbe C, Pillebout E, Martinez F, Legendre C, Thervet E. Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. Transplantation. 2005;80(11):1546–9.

    Article  CAS  PubMed  Google Scholar 

  55. Haycox CL, Kim S, Fleckman P, Smith LT, Piepkorn M, Sundberg JP, Howell DN, Miller SE. Trichodysplasia spinulosa—a newly described folliculocentric viral infection in an immunocompromised host. J Investig Dermatol Symp Proc. 1999;4(3):268–71.

    Article  CAS  PubMed  Google Scholar 

  56. van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN, Gorbalenya AE, Feltkamp MC. Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient. PLoS Pathog. 2010;6(7):e1001024.

    Article  PubMed  PubMed Central  Google Scholar 

  57. van der Meijden E, Kazem S, Burgers MM, Janssens R, Bouwes Bavinck JN, de Melker H, Feltkamp MC. Seroprevalence of trichodysplasia spinulosa-associated polyomavirus. Emerg Infect Dis. 2011;17(8):1355–63.

    PubMed  PubMed Central  Google Scholar 

  58. Holzer AM, Hughey LC. Trichodysplasia of immunosuppression treated with oral valganciclovir. J Am Acad Dermatol. 2009;60(1):169–72.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005;352(13):1317–23.

    Article  CAS  PubMed  Google Scholar 

  60. Mbulaiteye SM, Engels EA. Kaposi's sarcoma risk among transplant recipients in the United States (1993-2003). Int J Cancer. 2006;119(11):2685–91.

    Article  CAS  PubMed  Google Scholar 

  61. Shepherd FA, Maher E, Cardella C, Cole E, Greig P, Wade JA, Levy G. Treatment of Kaposi’s sarcoma after solid organ transplantation. J Clin Oncol. 1997;15(6):2371–7.

    Article  CAS  PubMed  Google Scholar 

  62. Ma T, Jham BC, Hu J, Friedman ER, Basile JR, Molinolo A, Sodhi A, Montaner S. Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma. Proc Natl Acad Sci U S A. 2010;107(32):14363–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, Gutkind JS. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res. 2000;60(17):4873–80.

    CAS  PubMed  Google Scholar 

  64. Campistol JM, Schena FP. Kaposi's sarcoma in renal transplant recipients—the impact of proliferation signal inhibitors. Nephrol Dial Transplant. 2007;22(Suppl 1):i17–22.

    Article  CAS  PubMed  Google Scholar 

  65. Lebbe C, Euvrard S, Barrou B, Pouteil-Noble C, Garnier JL, Glotz D, Legendre C, Frances C. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant. 2006;6(9):2164–8.

    Article  CAS  PubMed  Google Scholar 

  66. Wasywich CA, Croxson MC, van Doornum GJ, Coverdale HA, Ruygrok PN. Sirolimus for Kaposi’s sarcoma. J Heart Lung Transplant. 2006;25(6):726–9.

    Article  PubMed  Google Scholar 

  67. Dyall-Smith D, Trowell H, Dyall-Smith ML. Benign human papillomavirus infection in renal transplant recipients. Int J Dermatol. 1991;30(11):785–9.

    Article  CAS  PubMed  Google Scholar 

  68. Boyle J, MacKie RM, Briggs JD, Junor BJ, Aitchison TC. Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet. 1984;1(8379):702–5.

    Article  CAS  PubMed  Google Scholar 

  69. Schmook T, Nindl I, Ulrich C, Meyer T, Sterry W, Stockfleth E. Viral warts in organ transplant recipients: new aspects in therapy. Br J Dermatol. 2003;149(Suppl 66):20–4.

    Article  PubMed  Google Scholar 

  70. Blessing K, McLaren KM, Benton EC, Barr BB, Bunney MH, Smith IW, Beveridge GW. Histopathology of skin lesions in renal allograft recipients—an assessment of viral features and dysplasia. Histopathology. 1989;14(2):129–39.

    Article  CAS  PubMed  Google Scholar 

  71. de Lima AM, da Rocha SP, Reis Filho EG, Eid DR, Reis CM. Study of dermatoses in kidney transplant patients. An Bras Dermatol. 2013;88(3):361–7.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Chovatiya RJ, Colegio OR. Demodicosis in renal transplant recipients. Am J Transplant. 2016;16(2):712–6.

    Article  CAS  PubMed  Google Scholar 

  73. Salim A, Reece SM, Smith AG, Harrison D, Ramsay HM, Harden PN, Fryer AA. Sebaceous hyperplasia and skin cancer in patients undergoing renal transplant. J Am Acad Dermatol. 2006;55(5):878–81.

    Article  PubMed  Google Scholar 

  74. de Berker DA, Taylor AE, Quinn AG, Simpson NB. Sebaceous hyperplasia in organ transplant recipients: shared aspects of hyperplastic and dysplastic processes? J Am Acad Dermatol. 1996;35(5 Pt 1):696–9.

    Article  PubMed  Google Scholar 

  75. McDonald SK, Goh MS, Chong AH. Successful treatment of cyclosporine-induced sebaceous hyperplasia with oral isotretinoin in two renal transplant recipients. Australas J Dermatol. 2011;52(3):227–30.

    Article  PubMed  Google Scholar 

  76. Perrett CM, McGregor J, Barlow RJ, Karran P, Proby C, Harwood CA. Topical photodynamic therapy with methyl aminolevulinate to treat sebaceous hyperplasia in an organ transplant recipient. Arch Dermatol. 2006;142(6):781–2.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of California San Francisco School of Medicine, San Francisco, CT, USA

    Lucinda Kohn M.D.

  2. Department of Dermatology, Yale School of Medicine, New Haven, CT, 06520, USA

    Oscar R. Colegio M.D., Ph.D.

Authors
  1. Lucinda Kohn M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oscar R. Colegio M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oscar R. Colegio M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA

    Oscar R. Colegio

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kohn, L., Colegio, O.R. (2018). Benign Cutaneous Eruptions After Transplantation. In: Colegio, O. (eds) Skin Diseases in the Immunosuppressed. Springer, Cham. https://doi.org/10.1007/978-3-319-68790-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-68790-2_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-68788-9

  • Online ISBN: 978-3-319-68790-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation